Measurement of coagulation factor antibody levels is useful for diagnosis and determining therapeutic efficacy in hemorrhagic patients with autoantibodies to coagulation factor VIII and factor V: results from a single center in Japan

[1]  Y. Komiyama,et al.  Expert consensus regarding standardization of sample preparation for clotting time assays , 2020, International Journal of Hematology.

[2]  E. Gouider,et al.  Haemodialysis Tunisian patient with acquired factor V inhibitor associated to arteriovenous shunt thrombosis. , 2020, Annales de Biologie Clinique.

[3]  E. Lippert,et al.  A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome , 2019, European Journal of Haematology.

[4]  J. Oldenburg,et al.  Laboratory Monitoring in Emicizumab-Treated Persons with Hemophilia A , 2019, Thrombosis and Haemostasis.

[5]  K. Ohmura,et al.  Lupus anticoagulant-hypoprothrombinemia syndrome and similar diseases: experiences at a single center in Japan , 2019, International Journal of Hematology.

[6]  H. Narahara,et al.  High Titer of Acquired Factor V Inhibitor Presenting with a Pseudo-deficiency of Multiple Coagulation Factors , 2017, Internal medicine.

[7]  A. Ichinose.  The present condition of and clinical guidance for autoimmune coagulation factor deficiencies in Japan , 2018 .

[8]  P. Cortesi,et al.  Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. , 2017, Blood advances.

[9]  F. Boland.  Docetaxel Induced Myositis , 2017 .

[10]  F. Boland.  Acquired Factor V Inhibitors: A Review of Literature , 2017 .

[11]  C. Königs,et al.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A. , 2017, Blood.

[12]  W. H. Baldwin,et al.  High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. , 2016, Blood.

[13]  P. Knöbl,et al.  Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH‐AH 01/2010 study , 2016, Journal of thrombosis and haemostasis : JTH.

[14]  P. Knöbl,et al.  Diagnostic and Prognostic Value of Factor VIII Binding Antibodies in Acquired Hemophilia A: Data from the GTH-AH 01/2010 Study , 2015 .

[15]  M. Morfini,et al.  Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. , 2015, Blood transfusion = Trasfusione del sangue.

[16]  J. Oldenburg,et al.  Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. , 2015, Blood.

[17]  A. Khalafallah,et al.  Bleeding associated with acquired factor V inhibitor in a patient on warfarin treated successfully with prednisolone , 2013, BMJ Case Reports.

[18]  J. Goudemand,et al.  Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[19]  R. Liesner,et al.  Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition) , 2013, British journal of haematology.

[20]  F. Pellegrini,et al.  Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. , 2012, Blood.

[21]  T. Okamoto,et al.  Deep vein thrombosis associated with factor V inhibitor followed by immune thrombocytopenia , 2012, Annals of Hematology.

[22]  C. Kessler,et al.  Acquired Inhibitors to Factor VIII , 2010 .

[23]  E. Duncan,et al.  Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[24]  C. Kessler,et al.  Consensus recommendations for the diagnosis and treatment of acquired hemophilia A , 2010, BMC Research Notes.

[25]  B. Verbruggen.  Diagnosis and quantification of factor VIII inhibitors , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[26]  M. Koerper,et al.  Factor V deficiency: a concise review , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  L. Nemes,et al.  Chapter 16. Acquired Inhibitors to Factor VIII , 2008 .

[28]  J. Takamatsu,et al.  A 3-year consecutive survey on current status of acquired inhibitors against coagulation factors in Japan , 2008 .

[29]  T. Baglin,et al.  Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. , 2007, Blood.

[30]  P. Lollar.  Pathogenic antibodies to coagulation factors. Part one: Factor VIII and Factor IX , 2004, Journal of thrombosis and haemostasis : JTH.

[31]  I. Scharrer,et al.  In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. , 2001, Thrombosis research.

[32]  D. Keeling,et al.  THE DIAGNOSIS and MANAGEMENT OF FACTOR VIII and IX INHIBITORS: A GUIDELINE FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANIZATION (UKHCDO) , 2000, British journal of haematology.

[33]  C. Hay.  1 Acquired haemophilia , 1998 .

[34]  I. Scharrer,et al.  The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. , 1997, Blood.

[35]  M. van den Berg,et al.  The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability , 1995, Thrombosis and Haemostasis.

[36]  S. Mehta,et al.  Acquired haemophilia. , 1990, The Journal of the Association of Physicians of India.